Epigemomics' clinical trials are crucial to the validation of new biomarkers and  assays for molecular cancer diagnostics.

We place a high priority on communicating information about studies that are currently enrolling subjects as well as on ensuring that clinical trial results for completed studies are available to physicians and other interested parties.